News | April 07, 2025
Sumitomo Chemical establishes a CRO for Oligonucleotide CDMO business in US
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
Approval is based on positive data from the Phase 3 ECHELON-3 trial
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
The company uses iPS cells to develop treatments for diseases relating to the kidney
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Subscribe To Our Newsletter & Stay Updated
